TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration
Brief Summary: This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.


Options:
A: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
B: Arm Label: Ranibizumab 0.5mg Q4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4; Type: EXPERIMENTAL; Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Arm Label: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4; Type: EXPERIMENTAL; Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Arm Label: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8; Type: EXPERIMENTAL; Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Intervention Type: BIOLOGICAL; Name: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8
C: Arm Label: ranibizumab 0.5mg Q4; Type: ACTIVE_COMPARATOR; Interventions: Biological: ranibizumab | Arm Label: aflibercept injection 2.0mg Q4; Type: EXPERIMENTAL; Interventions: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Arm Label: aflibercept injection 0.5mg Q4; Type: EXPERIMENTAL; Interventions: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Arm Label: aflibercept injection 2.0mg Q8; Type: EXPERIMENTAL; Interventions: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Intervention Type: BIOLOGICAL; Name: ranibizumab; Assigned to Arm(s): ranibizumab 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): aflibercept injection 2.0mg Q4 | Intervention Type: BIOLOGICAL; Name: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): aflibercept injection 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): aflibercept injection 2.0mg Q8
D: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis


Options:
A: Arm Label: ISV-403; Type: EXPERIMENTAL; Interventions: Drug: ISV-403 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: ISV-403; Assigned to Arm(s): ISV-403 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle
B: Arm Label: Moxifloxacin AF; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5% | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Other: Moxifloxacin AF Vehicle | Intervention Type: DRUG; Name: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%; Assigned to Arm(s): Moxifloxacin AF | Intervention Type: OTHER; Name: Moxifloxacin AF Vehicle; Assigned to Arm(s): Vehicle
C: Arm Label: ISV-403; Type: EXPERIMENTAL; Interventions: Drug: ISV-403 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle | Intervention Type: DRUG; Name: ISV-403; Assigned to Arm(s): ISV-403 | Intervention Type: DRUG; Name: Vehicle; Assigned to Arm(s): Vehicle
D: Arm Label: Gatifloxacin 0.5% Eye Drops; Type: EXPERIMENTAL; Interventions: Drug: Gatifloxacin 0.5% eye drops | Arm Label: Placebo Eye Drops; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo eye drops | Intervention Type: DRUG; Name: Gatifloxacin 0.5% eye drops; Assigned to Arm(s): Gatifloxacin 0.5% Eye Drops | Intervention Type: DRUG; Name: placebo eye drops; Assigned to Arm(s): Placebo Eye Drops

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET)
Brief Summary: To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia Myelofibrosis (PET-MF).


Options:
A: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib
B: Arm Label: Treatment (lenalidomide, prednisone); Type: EXPERIMENTAL; Interventions: Drug: lenalidomide, Drug: prednisone, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): Treatment (lenalidomide, prednisone) | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Treatment (lenalidomide, prednisone) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Treatment (lenalidomide, prednisone)
C: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Arm Label: Best Available Therapy (BAT); Type: ACTIVE_COMPARATOR; Interventions: Drug: Best Available Therapy (BAT) | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib | Intervention Type: DRUG; Name: Best Available Therapy (BAT); Assigned to Arm(s): Best Available Therapy (BAT)
D: Arm Label: Lenalidomide + Prednisone; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide, Drug: Prednisone | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Lenalidomide + Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Lenalidomide + Prednisone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial
Brief Summary: To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone.


Options:
A: Arm Label: Phenobarbital; Type: EXPERIMENTAL; Interventions: Drug: Phenobarbital | Arm Label: Chlorpromazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorpromazine | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Intervention Type: DRUG; Name: Phenobarbital; Assigned to Arm(s): Phenobarbital | Intervention Type: DRUG; Name: Chlorpromazine; Assigned to Arm(s): Chlorpromazine | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine
B: Arm Label: Clonidine; Type: EXPERIMENTAL; Interventions: Drug: Clonidine | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine Sulfate | Intervention Type: DRUG; Name: Clonidine; Assigned to Arm(s): Clonidine | Intervention Type: DRUG; Name: Morphine Sulfate; Assigned to Arm(s): Morphine
C: Arm Label: Oral morphine sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine Sulfate | Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine | Intervention Type: DRUG; Name: Morphine Sulfate; Assigned to Arm(s): Oral morphine sulfate
D: Arm Label: Clonidine treatment; Type: EXPERIMENTAL; Interventions: Drug: Clonidine HCL | Intervention Type: DRUG; Name: Clonidine HCL; Assigned to Arm(s): Clonidine treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial
Brief Summary: To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone.


Options:
A: Arm Label: methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Arm Label: morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): methadone | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): morphine
B: Arm Label: Clonidine treatment; Type: EXPERIMENTAL; Interventions: Drug: Clonidine HCL | Intervention Type: DRUG; Name: Clonidine HCL; Assigned to Arm(s): Clonidine treatment
C: Arm Label: Oral morphine solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral morphine solution | Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine | Intervention Type: DRUG; Name: buprenorphine; Assigned to Arm(s): Buprenorphine | Intervention Type: DRUG; Name: Oral morphine solution; Assigned to Arm(s): Oral morphine solution
D: Arm Label: Music Therapy; Type: EXPERIMENTAL; Interventions: Other: Music Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Music Therapy; Assigned to Arm(s): Music Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-blind Phase III Study of RAD001 10 mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET)
Brief Summary: The purpose of this study was to evaluate progression free survival in those participants assigned everolimus 10 mg/day plus Best Supportive Care versus those assigned to placebo plus Best Supportive Care in Advanced Neuroendocrine Tumors of pancreatic origin.


Options:
A: Arm Label: Everolimus 10 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus 10 mg/day | Intervention Type: DRUG; Name: Everolimus Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Everolimus + BSC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Other: Best suportive care (BSC) | Arm Label: Placebo + BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best suportive care (BSC) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + BSC | Intervention Type: OTHER; Name: Best suportive care (BSC); Assigned to Arm(s): Everolimus + BSC, Placebo + BSC
C: Arm Label: Lanreotide Autogel (Somatuline Depot) 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide | Arm Label: Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lanreotide; Assigned to Arm(s): Lanreotide Autogel (Somatuline Depot) 120 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE
D: Arm Label: BEZ235; Type: EXPERIMENTAL; Interventions: Drug: BEZ235 | Arm Label: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: BEZ235; Assigned to Arm(s): BEZ235 | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Olanzapine in the Treatment of Patients With Bipolar I Disorder, Depressed: A Randomized, Double-Blind Comparison With Placebo
Brief Summary: The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression.


Options:
A: Arm Label: Olanzapine; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Olanzapine (open-label treatment period); Type: EXPERIMENTAL; Interventions: Drug: Olanzapine | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine, Olanzapine (open-label treatment period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Naltrexone 50mg; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Naltrexone 25mg; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone 25mg, Naltrexone 50mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Melatonin; Type: EXPERIMENTAL; Interventions: Drug: Melatonin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): Melatonin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Olanzapine/standard behavioral weight intervention; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine, Behavioral: Standard behavioral weight intervention | Arm Label: Olanzapine/intense behavioral weight intervention; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine, Behavioral: Intense behavioral weight intervention | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine/intense behavioral weight intervention, Olanzapine/standard behavioral weight intervention | Intervention Type: BEHAVIORAL; Name: Standard behavioral weight intervention; Assigned to Arm(s): Olanzapine/standard behavioral weight intervention | Intervention Type: BEHAVIORAL; Name: Intense behavioral weight intervention; Assigned to Arm(s): Olanzapine/intense behavioral weight intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Italian Elderly ACS Study
Brief Summary: A randomized study comparing an early aggressive with an initially conservative strategy in patients \>74 y.o. with non-ST-elevation acute coronary syndrome.

This study had generated a secondary one:

"Causes of death in elderly patients with Non-ST-Elevation Acute Coronary Syndrome; predictors of in-hospital and follow-up death"


Options:
A: Arm Label: Early Coronary Intervention; Type: OTHER; Interventions: Procedure: Early Coronary Intervention | Arm Label: Delayed Coronary Intervention; Type: OTHER; Interventions: Procedure: Delayed Coronary Intervention | Intervention Type: PROCEDURE; Name: Early Coronary Intervention; Assigned to Arm(s): Early Coronary Intervention | Intervention Type: PROCEDURE; Name: Delayed Coronary Intervention; Assigned to Arm(s): Delayed Coronary Intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: systematic coronary intervention | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Other: coronary intervention only for cases refractory to medical therapy | Intervention Type: OTHER; Name: systematic coronary intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: coronary intervention only for cases refractory to medical therapy; Assigned to Arm(s): 2
C: Arm Label: Radial; Type: EXPERIMENTAL; Interventions: Procedure: Radial approach | Arm Label: Femoral; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Femoral approach | Intervention Type: PROCEDURE; Name: Femoral approach; Assigned to Arm(s): Femoral | Intervention Type: PROCEDURE; Name: Radial approach; Assigned to Arm(s): Radial
D: Arm Label: Immediate Intervention; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Timing of percutaneous coronary intervention | Arm Label: Early Intervention; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Timing of percutaneous coronary intervention | Arm Label: Selective invasive angiography; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Timing of percutaneous coronary intervention | Intervention Type: PROCEDURE; Name: Timing of percutaneous coronary intervention; Assigned to Arm(s): Early Intervention, Immediate Intervention, Selective invasive angiography

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The DESTINY Trial: a Prospective Randomized Multicenter Trial Comparing the Implant of a Drug Eluting Stent (XIENCE V, Abbott Vascular) vs. a Bare Metal Stent (MULTILINK VISION, Abbott Vascular) in the Critically Ischemic Lower Leg
Brief Summary: The Destiny trial compares the use of bare metal stent systems with drug eluting stent systems in the treatment of infrapopliteal lesions in patients with Critical Limb Ischemia. It will be investigated whether there is a difference in 12 month angiographic patency of the stented area using the 2 different stent systems.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: XIENCE V everolimus eluting coronary stent system | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Device: MULTILINK VISION coronary stent system | Intervention Type: DEVICE; Name: XIENCE V everolimus eluting coronary stent system; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: MULTILINK VISION coronary stent system; Assigned to Arm(s): 2
B: Arm Label: Astron Pulsar Stent; Type: EXPERIMENTAL; Interventions: Device: Astron Pulsar Stent | Arm Label: PTA alone; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA alone | Intervention Type: DEVICE; Name: Astron Pulsar Stent; Assigned to Arm(s): Astron Pulsar Stent | Intervention Type: DEVICE; Name: PTA alone; Assigned to Arm(s): PTA alone
C: Arm Label: balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: balloon angioplasty | Arm Label: Drug eluting stent; Type: EXPERIMENTAL; Interventions: Device: drug eluting stent | Intervention Type: DEVICE; Name: balloon angioplasty; Assigned to Arm(s): balloon angioplasty | Intervention Type: DEVICE; Name: drug eluting stent; Assigned to Arm(s): Drug eluting stent
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: PTA with placement of paclitaxel-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA | Intervention Type: DEVICE; Name: PTA with placement of paclitaxel-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: PTA; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Study, to Assess the Safety and Tolerability of 28 Days Treatment With NVA237 (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: This study assessed the safety/tolerability of 28 days of treatment with NVA237 100 µg and 200 µg once a day, compared to placebo in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD).


Options:
A: Arm Label: Olodaterol andTiotropium; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium, Drug: Olodaterol | Arm Label: Placebo and Tiotropium; Type: OTHER; Interventions: Drug: Tiotropium, Drug: Placebo matching Olodaterol | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Placebo and Tiotropium | Intervention Type: DRUG; Name: Placebo matching Olodaterol; Assigned to Arm(s): Placebo and Tiotropium | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Olodaterol andTiotropium | Intervention Type: DRUG; Name: Olodaterol; Assigned to Arm(s): Olodaterol andTiotropium
B: Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): N/A
C: Arm Label: NVA237 100 µg; Type: EXPERIMENTAL; Interventions: Drug: NVA237 100 µg | Arm Label: NVA237 200 µg; Type: EXPERIMENTAL; Interventions: Drug: NVA237 200 µg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NVA237 100 µg; Assigned to Arm(s): NVA237 100 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: NVA237 200 µg; Assigned to Arm(s): NVA237 200 µg
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: QAB149; Type: ACTIVE_COMPARATOR; Interventions: Drug: QAB149 | Arm Label: NVA237; Type: ACTIVE_COMPARATOR; Interventions: Drug: NVA237 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: QAB149; Assigned to Arm(s): QAB149 | Intervention Type: DRUG; Name: NVA237; Assigned to Arm(s): NVA237 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protocolized Care for Early Septic Shock
Brief Summary: The ProCESS study is large, 5-year, multicenter study of alternative resuscitation strategies for septic shock. The study hypothesizes that there are "golden hours" in the initial management of septic shock where prompt, rigorous, standardized care can improve clinical outcomes.


Options:
A: Arm Label: Dopamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dopamine | Arm Label: Norepinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Norepinephrine | Intervention Type: DRUG; Name: Dopamine; Assigned to Arm(s): Dopamine | Intervention Type: DRUG; Name: Norepinephrine; Assigned to Arm(s): Norepinephrine
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: norepinephrine and dobutamine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epinephrine plus placebo of dobutamine | Intervention Type: DRUG; Name: norepinephrine and dobutamine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: epinephrine plus placebo of dobutamine; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Early Goal Directed Therapy (EGDT) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Protocolized Standard Care (PSC) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual Care (UC) | Intervention Type: PROCEDURE; Name: Early Goal Directed Therapy (EGDT); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Protocolized Standard Care (PSC); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Usual Care (UC); Assigned to Arm(s): 3
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: vasopressin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline control | Intervention Type: DRUG; Name: normal saline control; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: vasopressin; Assigned to Arm(s): I

Answer: C